Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.

Journal of hepato-biliary-pancreatic sciences2020Eso Y, Nakano S, Mishima M, et al.

Study designOther primary literature

SubjectHuman

Abstract

cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。

Amino Acids, Branched-ChainCarcinoma, HepatocellularHumansLiver NeoplasmsPhenylurea CompoundsQuinolinesTyrosine

DOI 10.1002/jhbp.821

PMID 32894808